ArticleOpen life sciences2026
The Th17/Treg axis: a key to understanding and treating autoimmune disorders.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Integrin Signature of Ankylosing Spondylitis: Divergent Regulation of CD29 and CD49b in HLA-B27-Positive Cohorts in Iraqi Patients.Iranian journal of pathology · 2026Article
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies.Frontiers in immunology · 2026Review
- T cells in Group AFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In autoimmune rheumatic diseases (ARDs), T cells mistakenly attack the body's own joints, skin, blood vessels, and other tissues, leading to chronic inflammation and tissue damage. Among these, the immune balance between T helper 17 lymphocytes (Th17) and regulatory T lymphocytes (Treg) is a foundation for maintaining normal immune function in the human body. An immune imbalance between Th17 and Treg cells is one of the key pathogenic mechanisms in ARDs. The percentages of Th17 and Treg cells can serve as important indicators for the severity of autoimmune diseases and treatment response. Therefore, by studying the origin and function of Th17 and Treg cells as well as the cytokine microenvironment that regulates their differentiation, we aim to modulate the immune state by restoring cellular balance. This approach is particularly relevant in ARDs such as rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, scleroderma, and ankylosing spondylitis. It also summarizes the current clinical application of disease-modifying anti-rheumatic drugs in regulating the balance between Th17 and Treg cells, with the aim of providing guidance for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.